Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next

Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.

By Alexandra Pecci • Sept. 25, 2026

Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry

Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...

By PharmaVoice Staff • Sept. 25, 2026

Explore the Trendline➔

Emerging biotech

After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.  

By PharmaVoice staff

Where does FDA nominee Overton stand on vaccines and other key pharma issues?

Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on vaccine-related decisions and work to speed early drug R&D.

By Jonathan Gardner • Sept. 24, 2026

What J&J’s Spravato patent win could mean for psychedelic drugs

As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.

By Kelly Bilodeau • Sept. 24, 2026

Novo talks up drug launches in effort to win back investors

At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. 

By Jonathan Gardner • Sept. 23, 2026

Lilly stopped showing its phase 1 pipeline. Is it playing R&D chess?

Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while competitors are still reading the board.

By Sy Mukherjee • Sept. 23, 2026

CRO consolidation keeps rolling. What does that mean for pharma?

While M&A expands one-stop shop capabilities at large CROs, pharma companies could face tradeoffs around niche expertise and service continuity.

By Alexandra Pecci • Sept. 22, 2026

A hidden tradeoff in Trump’s MFN drug deals

The government has announced pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s drug spend.

By Kelly Bilodeau • Sept. 21, 2026

Where female participation in clinical trials has caught up — and where gaps remain

Getting more women into drug R&D remains critical for boosting health outcomes. But in some disease areas, pharma is still falling behind.

By Kelly Bilodeau • Sept. 16, 2026

3 KRAS drugs to watch as the field expands

Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark on the space.

By Kelly Bilodeau • Sept. 15, 2026

Making oral drug delivery more sustainable with measurable product-level data

How auditable LCA data can guide more informed sustainability decisions.

Sept. 14, 2026

Cancer still dominates pharma R&D. Obesity is gaining ground.

Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third of drugs target at least one rare disease.

By Alexandra Pecci • Sept. 11, 2026

Merck builds around Keytruda; prediction markets raise new risks

Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.

By PharmaVoice Staff • Sept. 11, 2026

Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”

By Kristin Jensen • Sept. 10, 2026

5 questions that could determine Alzheimer’s next chapter

“The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?

By Kelly Bilodeau • Sept. 9, 2026

Merck pairs ADCs with Keytruda in women’s cancer push

The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda patent cliff.

By Kelly Bilodeau • Sept. 9, 2026

FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders

After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said. 

By Kristin Jensen • Sept. 9, 2026

Prediction markets are putting a price on pharma’s secrets. Here’s what companies need to know.

As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners with access to sensitive information.

By Sy Mukherjee • Sept. 8, 2026

Gilead’s growing HIV franchise; cell therapy licensing deals plummet

The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.

By PharmaVoice Staff • Sept. 4, 2026

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

By Jonathan Gardner • Sept. 3, 2026

China’s clinical trial boom under scrutiny after 3 deaths come to light

Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths are reported.

By Kelly Bilodeau • Sept. 3, 2026

Gilead takes a ‘different’ approach to reaching the Black community with new HIV campaign

Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV prevention and PrEP use.

By Alexandra Pecci • Sept. 2, 2026

Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?

After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.

By Alexandra Pecci • Aug. 31, 2026

New data could widen use of AstraZeneca, Amgen immune disease drug

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

By Delilah Alvarado • Aug. 28, 2026

A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.

Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.

By Meagan Parrish • Aug. 28, 2026